All In Biotech

Drug Trial Radar · NCT04829916

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

A Phase 1b, Randomised, Double-Blind, Parallel Treatment Group Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RMC-035 in Subjects Undergoing Non-Emergent On-Pump Coronary Artery Bypass Graft and/or Valve Surgery

Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Mar 16, 2021

Primary completion

Jul 15, 2021

Study completion Jul 15, 2021

Sponsor

Lead sponsor
Guard Therapeutics ABIndustry
Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.

Conditions

  • Acute Kidney Injury (AKI)

Interventions

  • RMC-035Drug

    Multiple dosing during 48 hours following cardiac surgery

  • PlaceboDrug

    Multiple dosing during 48 hours following cardiac surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs)Time frame: Baseline through day 30
  2. Severity of AEsTime frame: Within 4 days from first dose of IMP

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Münster University Hospital

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.